BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lymphoma AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Prognosis
192 results:

  • 1. Clinical Management of Patients with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review.
    Khasraw M; Yalamanchili P; Santhanagopal A; Wu C; Salas M; Meng J; Karnoub M; Esker S; Felip E
    Adv Ther; 2024 May; 41(5):1815-1842. PubMed ID: 38509433
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. 2021 WHO Classification of Lung Cancer: Molecular Biology Research and Radiologic-Pathologic Correlation.
    Sasaki T; Kuno H; Hiyama T; Oda S; Masuoka S; Miyasaka Y; Taki T; Nagasaki Y; Ohtani-Kim SJ; Ishii G; Kaku S; Shroff GS; Kobayashi T
    Radiographics; 2024 Mar; 44(3):e230136. PubMed ID: 38358935
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Prognostic factors for invasive mucinous adenocarcinoma of the lung: systematic review and meta-analysis.
    Zhao T; Yi J; Luo D; Liu J; Fan X; Wu Q; Wang W
    World J Surg Oncol; 2024 Feb; 22(1):41. PubMed ID: 38303008
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. CCDC86 promotes the aggressive behavior of nasopharyngeal carcinoma by positively regulating egfr and activating the PI3K/Akt signaling.
    Wang Z; Zhou T; Chen X; Zhu X; Liao B; Liu J; Li S; Tan T; Liu Y
    Neoplasma; 2023 Dec; 70(6):761-776. PubMed ID: 38247332
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Tumor microenvironment in Hodgkin lymphoma: novel prognostic factors for assessing disease evolution.
    Turbatu A; Dobrea C; Stoian M; Barta CT; Halcu G; Birceanu A; Bordea AM; Ghimici CG; Oprea MM; Neacșu LD; Lupu AR; Coliță A
    J Med Life; 2023 Aug; 16(8):1201-1210. PubMed ID: 38024830
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. [Analysis of Clinicopathological Features on Spread Through Air Spaces
of Lung Adenocarcinoma].
    Fan L; Qin J; Lin X; Wu Y; He Z; He P
    Zhongguo Fei Ai Za Zhi; 2023 Sep; 26(9):650-658. PubMed ID: 37985151
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Clinical significance of TP53 alterations in advanced NSCLC patients treated with egfr, ALK and ROS1 tyrosine kinase inhibitors: An update.
    Moes-Sosnowska J; Szpechcinski A; Chorostowska-Wynimko J
    Tumour Biol; 2024; 46(s1):S309-S325. PubMed ID: 37840519
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. [Mechanism of Astragali Radix-Curcumae Rhizoma in treating gastric cancer based on network pharmacology and experimental verification].
    Tan XY; Tao J; Zhang Y; Gu RX
    Zhongguo Zhong Yao Za Zhi; 2023 Sep; 48(18):5056-5067. PubMed ID: 37802848
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Genomic Profiling of Primary Diffuse Large B-Cell lymphoma of the Central Nervous System Suggests Novel Potential Therapeutic Targets.
    Agostinelli C; Morandi L; Righi S; Cirillo L; Iommi M; Tonon C; Mazzatenta D; Zoli M; Rossi M; Bagnato G; Broccoli A; Lodi R; Zinzani PL; Sabattini E; Giannini C; Asioli S
    Mod Pathol; 2023 Dec; 36(12):100323. PubMed ID: 37678673
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Investigation of egfr and ALK mutation frequency and treatment results in advanced non-small cell lung cancer.
    Komurcuoglu B; Karakurt G; Kaya OO; Diniz G; Kırbıyık O; Evkan A; Yalnız E
    J Cancer Res Ther; 2023 Apr; 19(Supplement):S183-S190. PubMed ID: 37147996
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Antitumoral effects of Bortezomib in malignant mesothelioma: evidence of mild endoplasmic reticulum stress in vitro and activation of T cell response in vivo.
    Benvenuto M; Angiolini V; Focaccetti C; Nardozi D; Palumbo C; Carrano R; Rufini A; Bei R; Miele MT; Mancini P; Barillari G; Cirone M; Ferretti E; Tundo GR; Mutti L; Masuelli L; Bei R
    Biol Direct; 2023 Apr; 18(1):17. PubMed ID: 37069690
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Survival Benefits of Radiotherapy and Surgery in Lung Cancer Brain Metastases with Poor prognosis Factors.
    Liang L; Wang Z; Duan H; He Z; Lu J; Jiang X; Hu H; Li C; Yu C; Zhong S; Cui R; Guo X; Deng M; Chen Y; Du X; Wu S; Chen L; Mou Y
    Curr Oncol; 2023 Feb; 30(2):2227-2236. PubMed ID: 36826133
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance.
    Wu J; Lin Z
    Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499382
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Image-guided thermal ablation for patients with epidermal growth factor receptor-mutant nonsmall cell lung cancer.
    Huang Y; Kong Y; Wei Z; Ye X
    Asia Pac J Clin Oncol; 2023 Aug; 19(4):427-433. PubMed ID: 36480416
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Concurrent classic driver oncogenes mutation with ROS1 rearrangement predicts superior clinical outcome in NSCLC patients.
    Li D; Jiang H; Jin F; Pan L; Xie Y; Zhang L; Li C
    Genes Genomics; 2023 Jan; 45(1):93-102. PubMed ID: 36445572
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.
    Zhang B; Zeng J; Zhang H; Zhu S; Wang H; He J; Yang L; Zhou N; Zu L; Xu X; Song Z; Xu S
    Front Immunol; 2022; 13():974581. PubMed ID: 36159860
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Advances in the treatment of postoperative recurrence of non-small cell lung cancer and their impact on survival in Asian patients.
    Hashimoto K; Ariyasu R; Ichinose J; Matsuura Y; Nakao M; Amino Y; Uchibori K; Kitazono S; Yanagitani N; Okumura S; Nishio M; Mun M
    J Thorac Cardiovasc Surg; 2023 Apr; 165(4):1565-1574.e1. PubMed ID: 36137840
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Different clinical characteristics and survival between surgically resected pure and combined small cell lung cancer.
    Li Y; Wang Y; Zhou W; Chen Y; Lou Y; Qian F; Lu J; Jiang H; Xiang B; Zhang Y; Han B; Zhang W
    Thorac Cancer; 2022 Oct; 13(19):2711-2722. PubMed ID: 36054506
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Targeted Therapies and Utility of the Lung-molGPA in Non-Small-Cell Lung Cancer Patients with Brain Metastases.
    Cacho-Díaz B; Cuapantécatl LD; Garcilazo-Reyes YJ; Cabrera-Miranda L; Hernandez-Martinez JM; Arrieta O
    Oncology; 2022; 100(10):542-554. PubMed ID: 35988535
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. CKAP2 overexpression correlates with worse overall survival in patients with lung adenocarcinoma.
    Zhang S; Li N; Yang Y; Li Y; Lin C; Fu G; Cai J
    Medicine (Baltimore); 2022 Jul; 101(30):e29796. PubMed ID: 35905213
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 10.